Centrosome Defects in Hematological Malignancies: Molecular Mechanisms and Therapeutic Insights. Issue 3 (14th July 2022)

• Record Type: Journal Article
• Authors: Hu, Mingzheng; Wang, Yijie; Zhou, Jun
• Is Part Of: Blood science. Volume 4:Issue 3(2022)
• Page Start: 143
• Page End: 151
• Publication Date: 2022-07-14
• Subjects: Centrosome defects -- Hematological malignancy -- Cell cycle regulators -- Cell surveillance pathways -- Pharmaceutical inhibitors; Hematology -- Periodicals; Blood -- Periodicals; Hematology; Blood; Hematology; Blood; Electronic journals; Periodicals; 616.15005
• DOI: 10.1097/BS9.0000000000000127
• Languages: English
• ISSNs: 2543-6368

Abstract

Abstract : Defects in centrosomes are associated with a broad spectrum of hematological malignancies, such as leukemia and lymphoma. Centrosomes in these malignancies display both numerical and structural aberrations, including alterations in the number and size of centrioles, inappropriate post-translational modification of centrosomal proteins, and extra centrosome clustering. There is accumulating evidence that centrosome defects observed in hematological malignancies result from multiple factors, including dysregulation of the centrosome cycle and impairment of centriole biogenesis. In this review, we discuss the plausible mechanisms of centrosome defects and highlight their consequences in hematological malignancies. We also illustrate the latest therapeutic strategies against hematological malignancies by targeting centrosome anomalies.